Novo Nordisk to license experimental GLP-1 pill from China's Hengrui

Novo Nordisk OMXCOP:NOVO_B will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental GLP-1 pill, the Chinese drugmaker said on Tuesday.The deal gains Novo a further potential revenue stream in the booming weight loss market, which analysts expect…